1-3 of 3
Philippa C. May
Close
Sort by
Journal Articles

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, MD, Maria Atta, MD, Irene Roberts, Holger W Auner, MD PhD, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris
Journal: Blood
Blood (2019) 134 (Supplement_1): 1769.
https://doi.org/10.1182/blood-2019-124761
Published: 2019
Journal Articles

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

Aristeidis Chaidos, Chris P. Barnes, Gillian Cowan, Philippa C. May, Valeria Melo, Evdoxia Hatjiharissi, Maria Papaioannou, Heather Harrington, Helen Doolittle, Evangelos Terpos, Meletios Dimopoulos, Saad Abdalla, Helen Yarranton, Kikkeri Naresh, Letizia Foroni, Alistair Reid, Amin Rahemtulla, Michael Stumpf, Irene Roberts, Anastasios Karadimitris
Journal: Blood
Blood (2013) 121 (2): 318–328.
https://doi.org/10.1182/blood-2012-06-436220
Published: 2013
Includes: Supplemental data
Journal Articles

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Brief Report
Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, Lihui Wang, Philippa C. May, Christos Paliompeis, Dragana Milojkovic, Valeria A. De Melo, Gareth Gerrard, John M. Goldman, Jane F. Apperley, Richard E. Clark, Letizia Foroni, Alistair G. Reid
Journal: Blood
Blood (2010) 116 (26): 6014–6017.
https://doi.org/10.1182/blood-2010-01-264234
Published: 2010
Includes: Supplemental data